The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | The real-world outcomes of patients with CLL who discontinue BTKi therapy
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the findings of the observational GIMEMA CLL2121 study (NCT04867915), which investigated the real-world outcomes of patients with chronic lymphocytic leukemia (CLL) who discontinued BTK inhibitor (BTKi) treatment. The treatment discontinuation rate was higher in the real-world setting than that reported in clinical trials. Almost one-third of patients discontinued therapy due to disease progression, and the outcomes of these patients were poorer than those patients who discontinued BTKi therapy due to intolerance. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly, Merck; Speaker bureau: OctaPharma.
